136 related articles for article (PubMed ID: 38264789)
1. Personalized Chronomodulated 5-Fluorouracil Treatment: A Physiologically-Based Pharmacokinetic Precision Dosing Approach for Optimizing Cancer Therapy.
Marok FZ; Wojtyniak JG; Selzer D; Dallmann R; Swen JJ; Guchelaar HJ; Schwab M; Lehr T
Clin Pharmacol Ther; 2024 Jun; 115(6):1282-1292. PubMed ID: 38264789
[TBL] [Abstract][Full Text] [Related]
2. Clinical pharmacokinetics of 5-fluorouracil with consideration of chronopharmacokinetics.
Milano G; Chamorey AL
Chronobiol Int; 2002 Jan; 19(1):177-89. PubMed ID: 11962674
[TBL] [Abstract][Full Text] [Related]
3. [Dihydropyrimidine deshydrogenase (DPD): rhythm and consequences].
Barrat-Petit MA; Naulin-Ifi C; Mahler P; Milano G
Pathol Biol (Paris); 2005 Jun; 53(5):261-4. PubMed ID: 15939134
[TBL] [Abstract][Full Text] [Related]
4. Comparative pharmacokinetic study of continuous venous infusion fluorouracil and oral fluorouracil with eniluracil in patients with advanced solid tumors.
Adjei AA; Reid JM; Diasio RB; Sloan JA; Smith DA; Rubin J; Pitot HC; Alberts SR; Goldberg RM; Hanson LJ; Atherton P; Ames MM; Erlichman C
J Clin Oncol; 2002 Mar; 20(6):1683-91. PubMed ID: 11896120
[TBL] [Abstract][Full Text] [Related]
5. A predictive biomarker for altered 5-fluorouracil pharmacokinetics following repeated administration in a rat model of colorectal cancer.
Kobuchi S; Kuwano S; Imoto K; Okada K; Nishimura A; Ito Y; Shibata N; Takada K
Biopharm Drug Dispos; 2013 Oct; 34(7):365-76. PubMed ID: 23836081
[TBL] [Abstract][Full Text] [Related]
6. Predicting 5-fluorouracil toxicity: DPD genotype and 5,6-dihydrouracil:uracil ratio.
Sistonen J; Büchel B; Froehlich TK; Kummer D; Fontana S; Joerger M; van Kuilenburg AB; Largiadèr CR
Pharmacogenomics; 2014 Sep; 15(13):1653-66. PubMed ID: 25410891
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and bioequivalence of a combined oral formulation of eniluracil, an inactivator of dihydropyrimidine dehydrogenase, and 5-fluorouracil in patients with advanced solid malignancies.
Ochoa L; Hurwitz HI; Wilding G; Cohen D; Thomas JP; Schwartz G; Monroe P; Petros WP; Ertel VP; Hsieh A; Hoffman C; Drengler R; Magnum S; Rowinsky EK
Ann Oncol; 2000 Oct; 11(10):1313-22. PubMed ID: 11106122
[TBL] [Abstract][Full Text] [Related]
8. A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity.
Bocci G; Barbara C; Vannozzi F; Di Paolo A; Melosi A; Barsanti G; Allegrini G; Falcone A; Del Tacca M; Danesi R
Clin Pharmacol Ther; 2006 Oct; 80(4):384-95. PubMed ID: 17015056
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of eniluracil, a dihydropyrimidine dehydrogenase inactivator, and oral 5-fluorouracil with radiation therapy in patients with recurrent or advanced head and neck cancer.
Humerickhouse RA; Dolan ME; Haraf DJ; Brockstein B; Stenson K; Kies M; Sulzen L; Ratain MJ; Vokes EE
Clin Cancer Res; 1999 Feb; 5(2):291-8. PubMed ID: 10037177
[TBL] [Abstract][Full Text] [Related]
10. [Circadian variations of dihydropyrimidine dehydrogenase (DPD) activity in oral mucosa of healthy volunteers].
Barrat MA; Renée N; Mormont MC; Milano G; Levi F
Pathol Biol (Paris); 2003 Jun; 51(4):191-3. PubMed ID: 12852985
[TBL] [Abstract][Full Text] [Related]
11. Effects of a bolus injection of 5-fluorouracil on dihydropyrimidine dehydrogenase activity in rats receiving continuous infusion of 5-fluorouracil.
Kobuchi S; Hayashi A; Taniguchi M; Ito Y; Tamura T; Sakaeda T
Cancer Chemother Pharmacol; 2016 Sep; 78(3):517-23. PubMed ID: 27417318
[TBL] [Abstract][Full Text] [Related]
12. Individualized Dosing of Fluoropyrimidine-Based Chemotherapy to Prevent Severe Fluoropyrimidine-Related Toxicity: What Are the Options?
Knikman JE; Gelderblom H; Beijnen JH; Cats A; Guchelaar HJ; Henricks LM
Clin Pharmacol Ther; 2021 Mar; 109(3):591-604. PubMed ID: 33020924
[TBL] [Abstract][Full Text] [Related]
13. A simple and rapid high-performance liquid chromatographic (HPLC) method for 5-fluorouracil (5-FU) assay in plasma and possible detection of patients with impaired dihydropyrimidine dehydrogenase (DPD) activity.
Ciccolini J; Mercier C; Blachon MF; Favre R; Durand A; Lacarelle B
J Clin Pharm Ther; 2004 Aug; 29(4):307-15. PubMed ID: 15271097
[TBL] [Abstract][Full Text] [Related]
14. Phase I pharmacological study of continuous chronomodulated capecitabine treatment.
Roosendaal J; Jacobs BAW; Pluim D; Rosing H; de Vries N; van Werkhoven E; Nuijen B; Beijnen JH; Huitema ADR; Schellens JHM; Marchetti S
Pharm Res; 2020 May; 37(5):89. PubMed ID: 32382808
[TBL] [Abstract][Full Text] [Related]
15. Phase I and pharmacokinetic trial of weekly oral fluorouracil given with eniluracil and low-dose leucovorin to patients with solid tumors.
Grem JL; Harold N; Shapiro J; Bi DQ; Quinn MG; Zentko S; Keith B; Hamilton JM; Monahan BP; Donavan S; Grollman F; Morrison G; Takimoto CH
J Clin Oncol; 2000 Dec; 18(23):3952-63. PubMed ID: 11099325
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of an oral uracil loading test to identify DPD-deficient patients using a limited sampling strategy.
van Staveren MC; van Kuilenburg AB; Guchelaar HJ; Meijer J; Punt CJ; de Jong RS; Gelderblom H; Maring JG
Br J Clin Pharmacol; 2016 Mar; 81(3):553-61. PubMed ID: 26551538
[TBL] [Abstract][Full Text] [Related]
17. [Review of methods for determination of dihydropyrimidine dehydrogenase and possible application in screening previous chemotheraphy with 5-fluorouracil].
Ostapowicz A; Dołegowska B
Przegl Lek; 2012; 69(9):694-7. PubMed ID: 23401991
[TBL] [Abstract][Full Text] [Related]
18. Preclinical development of eniluracil: enhancing the therapeutic index and dosing convenience of 5-fluorouracil.
Paff MT; Baccanari DP; Davis ST; Cao S; Tansik RL; Rustum YM; Spector T
Invest New Drugs; 2000 Nov; 18(4):365-71. PubMed ID: 11081572
[TBL] [Abstract][Full Text] [Related]
19. Improving safety of fluoropyrimidine chemotherapy by individualizing treatment based on dihydropyrimidine dehydrogenase activity - Ready for clinical practice?
Meulendijks D; Cats A; Beijnen JH; Schellens JH
Cancer Treat Rev; 2016 Nov; 50():23-34. PubMed ID: 27589829
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of 5-fluorouracil pharmacokinetics in cancer patients with a c.1905+1G>A mutation in DPYD by means of a Bayesian limited sampling strategy.
van Kuilenburg AB; Häusler P; Schalhorn A; Tanck MW; Proost JH; Terborg C; Behnke D; Schwabe W; Jabschinsky K; Maring JG
Clin Pharmacokinet; 2012 Mar; 51(3):163-74. PubMed ID: 22339448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
